September 2024- Rivus Pharmaceuticals announced it has appointed Tom O’Neil as chief financial officer and Erin Lavelle as an independent member of its board of directors. Mr. O’Neil will handle leading the finance, accounting and corporate strategy functions for the company. Ms. Lavelle will lead the formation of the company’s Audit Committee.
“We are thrilled to welcome Tom as our chief financial officer. His wealth of experience in the biopharmaceutical industry as a CFO and deep ability in strategy, business/corporate development and commercialization will be critical as we continue to grow and advance our innovative pipeline of Controlled Metabolic Accelerators, which are designed to promote sustained body fat loss while preserving muscle mass,” said Jayson Dallas, M.D., chief executive officer, Rivus Pharmaceuticals.
Read More: Pfizer Appoints Elif Aral as Regional President for MERA Region
“Metabolic diseases stemming from obesity represent a significant global healthcare burden and Rivus is pioneering a new class of medicines which have exciting potential to transform the treatment landscape,” said Mr. O’Neil. Also, “I’m excited to be joining the company and look forward to working closely with Jayson and the management team and board on its next phase of growth.”
“The Rivus team’s proven expertise in the field of mitochondrial biology is unparalleled within the industry and has driven the rapid advancement of HU6 in metabolic dysfunction-associated steatohepatitis and obesity-related heart failure,” said Ms. Lavelle. Also, “I’m delighted to join Rivus’ board and look forward to sharing my experience and insights as the company advances its pipeline of Controlled Metabolic Accelerators.”
